We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Show more
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell...
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular...
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial PR Newswire LAUSANNE, Switzerland, Dec. 6, 2024 Company to host corporate update webcast to share results on December 11...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Dec. 2, 2024 LAUSANNE, Switzerland, Dec. 2, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:...
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update PR Newswire LAUSANNE, Switzerland, Nov. 7, 2024 LOTIS-5 full enrollment and LOTIS-7...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.05 | 2.5 | 2 | 2.21 | 1.8 | 1406509 | 2.01025073 | CS |
4 | 0.13 | 6.77083333333 | 1.92 | 3.49 | 1.8 | 1713870 | 2.58402186 | CS |
12 | -1.02 | -33.2247557003 | 3.07 | 3.49 | 1.8 | 808274 | 2.67311413 | CS |
26 | -0.61 | -22.9323308271 | 2.66 | 4.13 | 1.8 | 619600 | 2.87027072 | CS |
52 | 0.61 | 42.3611111111 | 1.44 | 6.04 | 1.18 | 666636 | 3.29470695 | CS |
156 | -17.53 | -89.5301327886 | 19.58 | 22.52 | 0.359908 | 509889 | 3.78625242 | CS |
260 | -27.95 | -93.1666666667 | 30 | 56.5899 | 0.359908 | 418868 | 9.16396947 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions